Publicaties star-shl medewerkers


Deelen JWT, Rottier WC, van Werkhoven CH, Woudt SHS, Buiting AGM, Dorigo-Zetsma JW, Kluytmans JWAJ, et al. [van Asselt GJ, Demeulemeester A] The burden of bacteremic and non-bacteremic Gram-negative infections: A prospective multicenter cohort study in a low-resistance country. J Infect. 2020 Oct 6;S0163-4453(20)30643-5. doi: 10.1016/j.jinf.2020.10.001.


Kartaram SW, van Norren K, Schoen E, Teunis M, Mensink M, Verschuren M, M'Rabet L, et al [Mohrmann K]. Kinetics of Physiological Responses as a Measure of Intensity and Hydration Status During Experimental Physical Stress in Human Volunteers. Front Physiol. 2020 Sep 4;11:1006. doi: 10.3389/fphys.2020.01006. PMID: 33013439; PMCID: PMC7498705.


Price CP, Fay M, Hopstaken RM. Point-of-Care Testing for D-Dimer in the Diagnosis of Venous Thromboembolism in Primary Care: A Narrative Review. Cardiol Ther 2020. doi.org/10.1007/s40119-020-00206-2


Cooke J, Llor C, Hopstaken R, Dryden M, Butler C. Respiratory tract infections (RTIs) in primary care: narrative review of C reactive protein (CRP) point-of-care testing (POCT) and antibacterial use in patients who present with symptoms of RTI. BMJ Open Respir Res. 2020 Sep;7(1):e000624. doi: 10.1136/bmjresp-2020-000624.


Loots FJ, Hopstaken RM, Jenniskens K, Frederix GWJ, van de Pol AC, Van den Bruel A, Oosterheert JJ, van Zanten ARH, Smits M, Verheij TJM. Development of a clinical prediction rule for sepsis in primary care: protocol for the TeSD-IT study. Diagn Progn Res 2020;4:12. doi: 10.1186/s41512-020-00080-5.


Hopstaken RM. POCT bij COVID-19; Is ‘test, test, test’ scheepsrecht? Farma Magazine 2020;4; 18-20.


Heerink J, Gemen E, Oudega R, Hopstaken RM, Geersing GJ, Kusters R. Analytical Performance and User-friendliness of five novel Point-of-Care D-dimer assays. Scand J Clin Lab Invest. 2020 May 27;1-8. doi: 10.1080/00365513.2020.1768586.


Hopstaken RM, Cals JWL, Kusters R. POCT-drive-thru voor COVID-19: schijn kan bedriegen. Ned Tijdschr Geneeskd. 2020;164:C4538


Hopstaken RM, Cals JWL. POCT bij COVID-19 nog stap te ver. Ned Tijdschr Geneeskd. 2020;164:C4524.


Boere TM, van Buul LW, Hopstaken RM, Hertogh CMPM. CRP point-of-care testing voor lage luchtweginfecties: een meerwaarde in het verpleeghuis? Tijdschr v Ouderengeneesk. 2020;2;17-22.


Boere T, van Buul LW, Hopstaken RM, Veenhuizen RB, van Tulder MW, Cals JWL, Verheij TJM, Hertogh CMPM. Using Point-of-care C-reactive protein to guide Antibiotic prescribing for lower Respiratory tract infections in Elderly nursing home residents (UPCARE): study design of a cluster Randomized Controlled Trial. BMC Health Serv Res. 2020 Feb 27;20(1):149. doi: 10.1186/s12913-020-5006-0.


Hopstaken RM. Het ándere lab. Point-of-care testing in de huisartsenpraktijk. Flexx uitgeverij, ’s Hertogenbosch. Publicatiedatum 30 januari 2020.


Deelen JWT, Rottier WC, van Werkhoven CH, Woudt SHS, Buiting AGM, Dorigo-Zetsma JW, et al; ISIS-AR study group [van Asselt GJ, Demeulemeester A]. The burden of bacteremic and non-bacteremic Gram-negative infections: A prospective multicenter cohort study in a low-resistance country. J Infect. 2020 Oct 6:S0163-4453(20)30643-5. doi: 10.1016/j.jinf.2020.10.001. Epub ahead of print. PMID: 33031834.


van der Zwaluw K, Witteveen S, Wielders L, van Santen M, Landman F, de Haan A, et al; Dutch CPE surveillance Study Group. [van Asselt GJ, Demeulemeester A] Molecular characteristics of carbapenemase-producing Enterobacterales in the Netherlands; results of the 2014-2018 national laboratory surveillance. Clin Microbiol Infect. 2020 Oct;26(10):1412.e7-1412.e12. doi: 10.1016/j.cmi.2020.01.027. Epub 2020 Feb 5. PMID: 32006688.


Hendriks ACA, Reubsaet FAG, Kooistra-Smid AMDM, Rossen JWA, Dutilh BE, Zomer AL, et al; IBESS group. [Demeulemeester A] Genome-wide association studies of Shigella spp. and Enteroinvasive Escherichia coli isolates demonstrate an absence of genetic markers for prediction of disease severity. BMC Genomics. 2020 Feb 10;21(1):138. doi: 10.1186/s12864-020-6555-7. PMID: 32041522; PMCID: PMC7011524.


Honsbeek M, Tjon-A-Tsien A, Stobberingh E, de Steenwinkel J, Melles DC, Lous J, Richardus JH, Voeten H. Low antimicrobial resistance in general practice patients in Rotterdam, the city with the largest proportion of immigrants in the Netherlands. Eur J Clin Microbiol Infect Dis. 2020 May;39(5):929-935. doi: 10.1007/s10096-019-03804-8. Epub 2020 Jan 6. PMID: 31907762; PMCID: PMC7182613.


Fontanella A, Vescovo G, Verso M; Caravaggio Investigators [Kruip MJHA]. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020 Apr 23;382(17):1599-1607. doi: 10.1056/NEJMoa1915103. Epub 2020 Mar 29. PMID: 32223112.


Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10. PMID: 32291094; PMCID:


Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020 Jul;191:148-150. doi: 10.1016/j.thromres.2020.04.041. Epub 2020 Apr 30. PMID: 32381264; PMCID: PMC7192101.


Blaauwgeers MW, van Asten I, Kruip MJHA, Beckers EAM, Coppens M, Eikenboom J, et al. The limitation of genetic testing in diagnosing patients suspected for congenital platelet defects. Am J Hematol. 2020 Jan;95(1):E26-E28. doi: 10.1002/ajh.25667. Epub 2019 Nov 13. PMID: 31659778; PMCID: PMC6916199.


van der Zwan M, Leebeek FWG, Sandberg Y, Kruip MJHA, Hesselink DA. Acquired haemophilia A after alemtuzumab therapy. Haemophilia. 2020 Jul 22. doi: 10.1111/hae.14107. Epub ahead of print. PMID: 32700327.


van Asten I, Blaauwgeers M, Granneman L, Heijnen HFG, Kruip MJHA, Beckers EAM, et al. Flow cytometric mepacrine fluorescence can be used for the exclusion of platelet dense granule deficiency. J Thromb Haemost. 2020 Mar;18(3):706-713. doi: 10.1111/jth.14698. Epub 2019 Dec 27. PMID: 31815339; PMCID: PMC7065135.


Preijers T, Schütte LM, Kruip MJHA, Cnossen MH, Leebeek FWG, van Hest RM, Mathôt RAA. Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia. Clin Pharmacokinet. 2020 Sep 16. doi: 10.1007/s40262-020-00936-5. Epub ahead of print. PMID: 32936401.


Punt MC, Waning ML, Mauser-Bunschoten EP, Kruip MJHA, Eikenboom J, Nieuwenhuizen L, et al. Maternal and neonatal bleeding complications in relation to peripartum management in women with Von Willebrand disease: A systematic review. Blood Rev. 2020 Jan;39:100633. doi: 10.1016/j.blre.2019.100633. Epub 2019 Oct 24. PMID: 31718817.


de Jager NCB, Bukkems LH, Heijdra JM, Hazendonk CHCAM, Fijnvandraat K, Meijer K, et al.; OPTI-CLOT group. [Kruip MJHA] One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P® /Humate P® treatment in von Willebrand disease patients. J Thromb Haemost. 2020 Feb;18(2):295-305. doi: 10.1111/jth.14652. Epub 2019 Oct 21. PMID: 31557387; PMCID: PMC7028136.


van Es J, Cheung YW, van Es N, Klok FA, Dronkers CEA, Ten Wolde M, et al [Kruip MJHA]. Short-term prognosis of breakthrough venous thromboembolism in anticoagulated patients. Thromb Res. 2020 Mar;187:125-130. doi: 10.1016/j.thromres.2020.01.010. Epub 2020 Jan 20. PMID: 31986475.


Abdi A, Kloosterman FR, Eckhardt CL, Male C, Castaman G, Fischer K, et al [Kruip MJHA]; INSIGHT Study Group. The factor VIII treatment history of non-severe hemophilia A. J Thromb Haemost. 2020 Sep 2. doi: 10.1111/jth.15076. Epub ahead of print. PMID: 32877570.


Dreijer AR, Kruip MJHA, Diepstraten J, Polinder S, Brouwer R, Mol PGM, Croles FN, Kragten E, Leebeek FWG, van den Bemt PMLA. Effect of antithrombotic stewardship on the efficacy and safety of antithrombotic therapy during and after hospitalization. PLoS One. 2020 Jun 25;15(6):e0235048. doi: 10.1371/journal.pone.0235048. PMID: 32584857; PMCID: PMC7316339.


Schol-Gelok S, de Maat MPM, Biedermann JS, van Gelder T, Leebeek FWG, Lijfering WM, et al [Kruip MJHA]. Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial. Br J Haematol. 2020 Sep;190(6):916-922. doi: 10.1111/bjh.16648. Epub 2020 Apr 16. PMID: 32301122; PMCID: PMC7539918.


Blaauwgeers MW, Kruip MJHA, Beckers EAM, Coppens M, Eikenboom J, van Galen KPM, et al. Bleeding phenotype and diagnostic characterization of patients with congenital platelet defects. Am J Hematol. 2020 Jun 19;95(10):1142–7. doi: 10.1002/ajh.25910. Epub ahead of print. PMID: 32562285; PMCID: PMC7540397.


Leebeek FWG, Duvekot J, Kruip MJHA. How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease. Blood. 2020 Nov 5;136(19):2143-2150. doi: 10.1182/blood.2019000964. PMID: 32797211.


Limperg PF, Maurice-Stam H, Heesterbeek MR, Peters M, Coppens M, Kruip MJHA, et al. Illness cognitions associated with health-related quality of life in young adult men with haemophilia. Haemophilia. 2020 Sep;26(5):793-799. doi: 10.1111/hae.14120. Epub 2020 Aug 25. PMID: 32842171.


Hendriks SV, den Exter PL, Zondag W, Brouwer R, Eijsvogel M, Grootenboers MJ, et al; Hestia/Vesta investigators.[Kruip MJHA] Reasons for Hospitalization of Patients with Acute Pulmonary Embolism Based on the Hestia Decision Rule. Thromb Haemost. 2020 Aug;120(8):1217-1220. doi: 10.1055/s-0040-1713170. Epub 2020 Jun 28. PMID: 32594509.


de Jager NCB, Heijdra JM, Pistorius M, Kruip MJHA, Leebeek FWG, Cnossen MH, et al. Novel Quantitative Method for Analyzing Desmopressin in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry. Ther Drug Monit. 2020 Dec;42(6):880-885. doi: 10.1097/FTD.0000000000000791. PMID: 32694360.


Hendriks SV, Bavalia R, van Bemmel T, Bistervels IM, Eijsvogel M, Faber LM, et al; YEARS investigators [Kruip MJHA]. Current practice patterns of outpatient management of acute pulmonary embolism: A post-hoc analysis of the YEARS study. Thromb Res. 2020 Sep;193:60-65. doi: 10.1016/j.thromres.2020.05.038. Epub 2020 May 30. PMID: 32521336.


de Jager NCB, Heijdra JM, Kieboom Q, Kruip MJHA, Leebeek FWG, Cnossen MH, et al; OPTI-CLOT Group. Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration. Thromb Haemost. 2020 Oct;120(10):1407-1416. doi: 10.1055/s-0040-1714349. Epub 2020 Aug 3. PMID: 32746466.


de Vries JJ, Veen CSB, Snoek CJM, Kruip MJHA, de Maat MPM. FIBTEM clot firmness parameters correlate well with the fibrinogen concentration measured by the Clauss assay in patients and healthy subjects. Scand J Clin Lab Invest. 2020 Nov;80(7):600-605. doi: 10.1080/00365513.2020.1818283. Epub 2020 Sep 14. PMID: 32924629.


Veen CSB, Huisman EJ, Cnossen MH, Kom-Gortat R, Rijken DC, Leebeek FWG, et al [Kruip MJHA]. Evaluation of thromboelastometry, thrombin generation and plasma clot lysis time in patients with bleeding of unknown cause: A prospective cohort study. Haemophilia. 2020 May;26(3):e106-e115. doi: 10.1111/hae.13991. Epub 2020 Apr 26. PMID: 32337845.


Schütte LM, Hodes LS, van Moort I, Stoof SCM, Leebeek FWG, Cnossen MH, et al. [Kruip MJHA]. The one-stage assay or chromogenic assay to monitor baseline factor VIII levels and desmopressin effect in non-severe haemophilia A: Superiority or non-inferiority? Haemophilia. 2020 Sep;26(5):916-922. doi: 10.1111/hae.14106. Epub 2020 Jul 26. PMID: 32713129; PMCID: PMC7590113.